drugset

drugset / Trial / NCT00901342

Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer

NCT00901342 ↗

Phase 2 Completed 104 enrolled Dendreon

NaSingle-groupOpen-labelTreatment

Summary

This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).

Timeline

Start: 2009-10
Primary completion: 2014-12
Completion: 2015-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sipuleucel-T	Cell therapy	—	Other

Indications